Gentamicin-impregnated chitosan/nanohydroxyapatite/ethyl cellulose microspheres granules for chronic osteomyelitis therapy

Journal of Biomedical Materials Research - Part A

Volumn 93, Issue 3, 2010, Pages 1020-1031

  Shi, Pujiang ^a   Zuo, Yi ^a   Li, Xiaowei ^b   Zou, Qin ^a   Liu, Haohuai ^a   Zhang, Li ^a   Li, Yubao ^a   Morsi, Yos S ^c  

^a SICHUAN UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Gentamicin release; Granule; Microsphere; Osteomyelitis

Indexed keywords

CELLULOSE MICROSPHERES; CURATIVE EFFECTS; CYTOTOXIC; DRUG RELEASE; DRUG RELEASE PROPERTIES; ETHYL CELLULOSE; GENTAMICIN RELEASE; IN-VITRO; IN-VIVO; INSPECTION METHODS; NANO-HYDROXYAPATITE; RABBIT MODELS; STAPHYLOCOCCUS AUREUS; X-RAY OBSERVATIONS;

CELL CULTURE; CELLULOSE; INSPECTION; MICROSPHERES; SODIUM; SPECIAL EFFECTS;

GRANULATION;

CHITOSAN; ETHYL CELLULOSE; GENTAMICIN; HYDROXYAPATITE; MICROSPHERE; MORRHUATE SODIUM; NANOHYDROXYAPATITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE RADIOGRAPHY; CELL VIABILITY; CHRONIC OSTEOMYELITIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG GRANULE; DRUG RELEASE; FIBROBLAST; IN VITRO STUDY; IN VIVO STUDY; MICRORADIOGRAPHY; NONHUMAN; OSTEOBLAST; RABBIT; RAT; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS;

ANIMALS; CELL DEATH; CELL SURVIVAL; CELLULOSE; CHITOSAN; CHRONIC DISEASE; DURAPATITE; FIBROBLASTS; GENTAMICINS; HUMANS; IMPLANTS, EXPERIMENTAL; MICROSPHERES; NANOSTRUCTURES; OSTEOBLASTS; OSTEOMYELITIS; RABBITS; RATS; RATS, WISTAR; STAPHYLOCOCCUS AUREUS; TIBIA;

CELLS; CELLULOSE; GRANULATION; GRANULES; INSPECTION; MICROSPHERES; SODIUM;

EID: 77950651081     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32598     Document Type: Article

References (56)

1. Stevens MM. Biomaterials for bone tissue engineering. Mater Today 2008;11:18-25.
2. Santos JD, Jha LJ, Monteiro FJ. Surface modifications of glass-reinforced hydroxyapatite composites. Biomaterials 1995;16:521-526.
3. Dean JC, Tisdel CL, Goldberg VM, Parr J, Davy D, Stevenson S. Effects of hydroxyapatite tricalcium phosphate coating and intracancellous placement on bone ingrowth in titanium fibermetal implants. J Arthroplasty 1995;10:830-838. (Pubitemid 26003250)
4. Liu DMO. Fabrication of hydroxyapatite ceramic with controlled porosity. J Mater Science Mater Med 1997;8:227-232.
5. Seal BL, Otero TC, Panitch A. Polymeric biomaterials for tissue and organ regeneration. Mater Sci Eng R Rep 2001;34:147-230. (Pubitemid 32842254)
6. Wang H, Li Y, Zuo Y, Li J, Ma S, Cheng L. Biocompatibility and osteogenesis of biomimetic nano-hydroxyapatite/polyamide composite scaffolds for bone tissue engineering. Biomaterials 2007;28:3338-3348. (Pubitemid 46693973)
7. Kong L, Gao Y, Lu G, Gong Y, Zhao N, Zhang X. A study on the bioactivity of chitosan/nano-hydroxyapatite composite scaffolds for bone tissue engineering. Eur Polym J 2006;42:3171-3179. (Pubitemid 44708907)
8. Jin HH, Lee CH, Lee WK, Lee JK, Park HC, Yoon SY. In-situ formation of the hydroxyapatite/chitosan-alginate composite scaffolds. Mater Lett 2008;62:1630-1633.
9. Sia IG, Berbari EF. Osteomyelitis. Best Pract Res Clin Rheumatol 2006;20:1065-1081.
10. Lew PDP, Waldvogel PFA. Osteomyelitis. Lancet 2004;364:369-379.
11. Sundin DP, Sandoval R, Molitoris BA. Gentamicin inhibits renal protein and phospholipid metabolism in rats: Implications involving intracellular trafficking. J Am Soc Nephrol 2001;12:114-123. (Pubitemid 32056796)
12. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998;15:1326-1331. (Pubitemid 28427917)
13. Papineau AM, Hoover DG, Knorr D, Farkas DF. Antimicrobial effect of water-soluble chitosans with high hydrostatic pressure. Food Biotechnol 1991;5:45-57.
14. El Ghaouth A, Ponnampalam R, Castaigne F, Arul J. Chitosan coating to extend the storage life of tomatoes. HortScience 1992;27:1016-1018.
15. Sudarshan NR, Hoover DG, Knorr D. Antibacterial action of chitosan. Food Biotechnol 1992;6:257-272.
16. Xie Y, Liu X, Chen Q. Synthesis and characterization of water-soluble chitosan derivate and its antibacterial activity. Carbohydr Polym 2007;69:142-147. (Pubitemid 46497422)
17. Chung YC, Wang HL, Chen YM, Li SL. Effect of abiotic factors on the antibacterial activity of chitosan against waterborne pathogens. Bioresour Technol 2003;88:179-184.
18. Liu XF, Guan YL, Yang DZ, Li Z, Yao KD. Antibacterial action of chitosan and carboxymethylated chitosan. J Appl Polym Sci 2001;79:1324-1335.
19. Xie W, Xu P, Wang W, Liu Q. Preparation of water-soluble chitosan derivatives and their antibacterial activity. J Appl Polym Sci 2002;85:1357-1361. (Pubitemid 34691242)
20. Hu Y, Du Y, Yang J, Tang Y, Li J, Wang X. Self-aggregation and antibacterial activity of N-acylated chitosan. Polymer 2007;48:3098-3106. (Pubitemid 46709990)
21. No HK, Kim SH, Lee SH, Park NY, Prinyawiwatkul W. Stability and antibacterial activity of chitosan solutions affected by storage temperature and time. Carbohydr Polym 2006;65:174-178.
22. Rowe RC, Kotaras AD, White EFT. An evaluation of the plasticizing efficiency of the dialkyl phthalates in ethyl cellulose films using the torsional braid pendulum. Int J Pharm 1984;22:57-62.
23. Porter SC. The effect of additives on the properties of an aqueous film coating. Pharm Tech 1980;3:67-75.
24. Anal AK, Stevens WF, Remunan-Lopez C. Ionotropic crosslinked chitosan microspheres for controlled release of ampicillin. Int J Pharm 2006;312:166-173.
25. Gunder W, Lippold BH, Lippold BC. Release of drugs from ethyl cellulose microcapsules (diffusion pellets) with pore formers and pore fusion. Eur J Pharm Sci 1995;3:203-214.
26. Abdel-Fattah WI, Jiang T, El-Bassyouni GET, Laurencin CT. Synthesis, characterization of chitosans and fabrication of sintered chitosan microsphere matrices for bone tissue engineering. Acta Biomaterialia 2007;3:503-514. (Pubitemid 46865775)
27. Nelson CL, Hickmon SG, Skinner RA. Treatment of experimental osteomyelitis by surgical debridement and the implantation of bioerodable, polyanhydride-gentamicin beads. J Orthopaedic Res 1997;15:249-255.
28. Ruf M, Stoltze D, Merk HR, Ames M, Harms J. Treatment of vertebral osteomyelitis by radical debridement and stabilization using titanium mesh cages. Spine 2007;32:E275-E280. (Pubitemid 46642564)
29. Nelson CL, McLaren SG, Skinner RA, Smeltzer MS, Roby TJ, Olsen KM. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J Orthopaedic Res 2002;20:643-647.
30. O'Brien DP, Athan E, Hughes A, Johnson PD. Successful treatment of mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: A case report. J Med Case Rep 2008;2:123. (Pubitemid 351827615)
31. Santoshi JA, Pallapati SC, Thomas BP. Haematogenous pseudomonas osteomyelitis of the hamate-treatment by radical debridement and bone grafting. J Plast Reconstr Aesthet Surg [Epub ahead of print (DOI: 10.1016/j.bjps.2008.08. 057)].
32. Yubao L, De Wijn J, Klein CPAT, Van de Meer S, De Groot K. Preparation and characterization of nanograde osteoapatite-like rod crystals. J Mater Science Mater Med 1994;5:252-255. (Pubitemid 24246276)
33. Shi P, Li Y, Zhang L. Fabrication and property of chitosan film carrying ethyl cellulose microspheres. Carbohydr Polym 2008;72:490-499. (Pubitemid 351288896)
34. Zhang X, Wyss UP, Pichora D, Goosen MFA. Biodegradable controlled antibiotic release devices for osteomyelitis: Optimization of release properties. J Pharm Pharmacol 1994;46:718-724. (Pubitemid 24289659)
35. Stead DA. Current methodologies for the analysis of aminoglycosides. J Chromatogr B: Biomed Sci Appl 2000;747:69-93.
36. Fennell MA, Uboh CE, Sweeney RW, Soma LR. Gentamicin in tissue and whole milk: An improved method for extraction and cleanup of samples for quantitation on HPLC. J Agric Food Chem 1995;43:1849-1852.
37. Lew DP, Waldvogel FA. Current concepts: Osteomyelitis. N Engl J Med 1997;336:999-1007.
38. Mader J, Davis J. General concept of osteomyelitis. Principles Practice Infect Dis 1995.
39. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: A review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med 1970;282:316-322.
40. Waldvogel FA, Vasey H. Osteomyelitis: The past decade. N Engl J Med 1980;303:360-370.
41. Cierny G III, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin orthopaedics Relat Res 2003;414:7-24.
42. Hudson MC, Ramp WK, Nicholson NC, Williams AS, Nousiainen MT. Internalization of Staphylococcus aureus by cultured osteoblasts. Microb Pathogenesis 1995;19:409-419.
43. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003;112:1466-1477. (Pubitemid 38056271)
44. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 2002;292:107-113. (Pubitemid 34842181)
45. Eckardt JJ, Wirganowicz PZ, Mar T. An aggressive surgical approach to the management of chronic osteomyelitis. Clin Orthopaedics Relat Res 1994;298:229-239. (Pubitemid 24023613)
46. Reese JH, Barrio J. Surgical approaches to the management of osteomyelitis. Diagn Manage Bone Infect 1995;425-429.
47. Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm 2004;282:1-18. (Pubitemid 39178480)
48. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm 2003;255:13-32. (Pubitemid 36369587)
49. Hewitt WL. Gentamicin: Toxicity in perspective. Postgrad Med J 1974;50:55-61.
50. Norden CW. Experimental osteomyelitis. I. A description of the model. J Infect Dis 1970;122:410-418.
51. Zak O, Zak F, Rich R. Experimental staphylococcal osteomyelitis in rats: Therapy with rifampin and cloxacillin alone or in combination. Current Chemotherapy and Immunotherapy. Proceedings of the Twelfth International Congress on Chemotherapy, 1982.
52. Fitzgerald RH Jr. Experimental osteomyelitis: Description of a canine model and the role of depot administration of antibiotics in the prevention and treatment of sepsis. J Bone Joint Surg Am 1983;65:371-380.
53. An YH, Kang QK, Arciola CR. Animal models of osteomyelitis. Int J Artif Organs 2006;29:407-420.
54. Scheman L, Janota M, Lewin P. The production of experimental osteomyelitis. JAMA 1941;117:1525-1529.
55. Stroncek DF, Hutton SW, Silvis SE, Vercellotti GM, Jacob HS, Hammerschmidt DE. Sodium morrhuate stimulates granulocytes and damages erythrocytes and endothelial cells: Probable mechanism of an adverse reaction during sclerotherapy. J Lab Clin Med 1985;106:498-504.
56. Goldman MP. Erratum: A comparison of sclerosing agents: Clinical and histologic effects of intravascular sodium morrhuate, ethanolamine oleate, hypertonic saline (11.7%), and sclerodex in the dorsal rabbit ear vein (J Dermatol Surg Oncol 1991;17:354-362). J Dermatol Surg Oncol 1991;17:691.